Effectiveness of a Computer-Tailored Smoking Cessation Program

Etter, Jean‐François; Perneger, Thomas

doi:10.1001/archinte.161.21.2596

Cited by 126 publications

(118 citation statements)

References 39 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…Overall, 30 studies 34,[36][37][38][39][40][42][43][44]46,48,49,53,[55][56][57][58]61,66,69,72,75,80,88,91,96,97,109,110 that randomised between 72 and 3627 participants and followed up between 3 and 30 months evaluated the effect of tailored printed materials. In the meta-analysis, computer-generated, tailored printed materials were effective in increasing smoking cessation compared with no intervention or generic self-help materials.…”

Section: Summary and Discussionmentioning

confidence: 99%

“…Tailored printed materials also appear to be effective in studies in which the smokers were not ready to quit at the start of the study, but there was significant heterogeneity in effect estimates (I 2 = 85%, p < 0.001). Overall, only five studies 53,56,88,97,109 demonstrated a statistically significant increase in abstinence rates in the intervention groups compared with the control groups. Figure 21 shows the results of point prevalence abstinence measured at the last follow-up of each study.…”

Section: Comparisons and Findingsmentioning

confidence: 94%

“…Figure 20 shows the results of point prevalence abstinence at 6 months, which was reported in 13 studies. 37,40,44,46,48,53,[55][56][57]61,97,109,110 Pooled result showed that computer-generated, tailored printed materials, when added to varied co-interventions, increase the likelihood of cessation in studies in which smokers are prepared to quit at the beginning of the studies (RR = 1.29, 95% CI 1.10 to 1.51). Tailored printed materials also appear to be effective in studies in which the smokers were not ready to quit at the start of the study, but there was significant heterogeneity in effect estimates (I 2 = 85%, p < 0.001).…”

Section: Comparisons and Findingsmentioning

confidence: 99%

See 2 more Smart Citations

Effectiveness and cost-effectiveness of computer and other electronic aids for smoking cessation: a systematic review and network meta-analysis.

Chen

Madan²,

Welton³

et al. 2012

Health Technol Assess

138

121

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service' . The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of project...

show abstract

Section: Summary and Discussionmentioning

confidence: 99%

Section: Comparisons and Findingsmentioning

confidence: 94%

Section: Comparisons and Findingsmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness and cost-effectiveness of computer and other electronic aids for smoking cessation: a systematic review and network meta-analysis.

Chen

Madan²,

Welton³

et al. 2012

Health Technol Assess

138

121

View full text Add to dashboard Cite

show abstract

“…Data were collected between September 2000 and June 2001. An invitation to fill the survey was sent by e-mail to 5000 smokers who participated in the 'Stop-tabac.ch' smoking cessation program (Etter and Perneger, 2001b). A link to the questionnaire was also posted on several pages of this site.…”

Section: Main Surveymentioning

confidence: 99%

A Self-Administered Questionnaire to Measure Dependence on Cigarettes: The Cigarette Dependence Scale

Etter

Houezec²,

Perneger

2003

Neuropsychopharmacol

Self Cite

281

211

View full text Add to dashboard Cite

A valid measure of dependence on cigarettes is a useful tool for clinicians and researchers. The aim of this study was to develop a new, self-administered measure of cigarette dependence, and to assess its validity. The content of the instrument was generated in qualitative surveys. A long version (114 items) was tested on the internet in 3009 smokers. Subsamples provided retest data after 18 days (n ¼ 578), follow-up data after 45 days (n ¼ 990) and saliva cotinine (n ¼ 105). The study resulted in a 12-item scale labelled the Cigarette Dependence Scale (CDS-12), and in a 5-item version of this scale (CDS-5). Except for tolerance, CDS-12 covers the main components of DSM-IV and ICD-10 definitions of dependence: compulsion, withdrawal symptoms, loss of control, time allocation, neglect of other activities, and persistence despite harm. CDS-5 has similar measurement properties but less comprehensive content. Both scales had a high test-retest reliability (rX0.83), and a high internal consistency (Cronbach's aX0.84). CDS-12 scores were higher in daily smokers than in occasional smokers (+1.3SD units), and were associated with the strength of the urge to smoke during the last quit attempt (R 2 X0.25), and with saliva cotinine (R 2 X0.17). CDS-12 and CDS-5 scores decreased in daily smokers who switched to occasional smoking at 18-day retest. Dependence scores did not predict smoking abstinence at follow-up. In conclusion, CDS-12 and CDS-5 are reliable measures of cigarette dependence which fulfill several criteria of content validity and construct validity and are sensitive to change over time.

show abstract

“…49 Concerns of neuropsychiatric harms of varenicline and bupropion also exist, including changes in mood (including depression and mania), psychosis, hallucinations, paranoia, delusions, homicidal ideation, hostility, agitation, aggression, anxiety, and panic, as well as suicidal ideation, suicide attempt, and completed suicide. 50,51 With most trials excluding patients with a history of neuropsychiatric disease, neuropsychiatric adverse event data are limited. However, the recently completed the EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study) trial found no increase in neuropsychiatric adverse events among patients randomized to varenicline or bupropion relative to those randomized to nicotine patch or placebo.…”

mentioning

confidence: 99%

Efficacy and Safety of Smoking Cessation Interventions in Patients With Cardiovascular Disease

Suissa

Larivière

Eisenberg³

et al. 2017

Circ: Cardiovascular Quality and Outcomes

View full text Add to dashboard Cite

1T he efficacy and safety of pharmacological and behavioral smoking cessation interventions have been examined in multiple randomized controlled trials (RCTs), with subsequent meta-analyses showing that such interventions are efficacious at increasing quit rates.1,2 However, participants in these trials were generally healthy, and the generalizability of these data to patients with cardiovascular disease (CVD) is unclear. This unclear generalizability is underscored by 3 trials that found that the smoking cessation drug bupropion did not increase the prevalence of abstinence when used in patients with acute manifestations of CVD. [3][4][5] This may be because of fundamental differences between such patients, who tend to have higher quit rates without therapy because of an increased motivation to quit and the teachable moment that occurs after an adverse event, 6 and the otherwise healthy smokers enrolled in previous RCTs. 6,7 Similarly, the generalizability of RCTs conducted in the general population to patients with stable CVD is also unknown. A thorough assessment of the effect of smoking cessation interventions in CVD patients is needed to develop tailored recommendations to increase abstinence in the CVD population. Consequently, we conducted a systematic review and network meta-analysis of RCTs to evaluate the relative efficacy and safety of pharmacological and behavioral smoking cessation interventions in CVD patients.Background-Although the efficacy and safety of smoking cessation interventions are well established, their efficacy and safety in patients with cardiovascular disease (CVD) remain unclear. The objective of this study was to evaluate the efficacy and safety of pharmacological and behavioral smoking cessation interventions in CVD patients via a metaanalysis of randomized controlled trials. Methods and Results-EMBASE, PsycINFO, MEDLINE, PubMed, and the Cochrane Tobacco Addiction SpecializedRegister were searched for randomized controlled trials evaluating the efficacy of smoking cessation pharmacotherapies and behavioral therapies in CVD patients. Outcomes of interest were smoking abstinence at 6 and 12 months, defined using the most rigorous criteria reported. Data were pooled across studies for direct comparisons using random-effects models. Network meta-analysis using a graph-theoretical approach was used to generate the indirect comparisons. Seven pharmacotherapy randomized controlled trials (n=2809) and 17 behavioral intervention randomized controlled trials (n=4666) met our inclusion criteria. Our network meta-analysis revealed that varenicline (relative risk [ MethodsOur systematic review and network meta-analysis was performed after a prespecified protocol and is reported using the guidelines described in PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) extension for reporting of systematic reviews incorporating network meta-analyses. 8 Data SourcesWe systematically searched Ovid EMBASE, Ovid PsycINFO, Ovid MEDLINE, PubMed, and the Cochrane Tobacco Addiction G...

show abstract

Effectiveness of a Computer-Tailored Smoking Cessation Program

Abstract: The program was effective in increasing smoking cessation rates. Because it can reach a large number of smokers, this program can substantially contribute to disease prevention at a population level.

Cited by 126 publications

References 39 publications

Effectiveness and cost-effectiveness of computer and other electronic aids for smoking cessation: a systematic review and network meta-analysis.

Effectiveness and cost-effectiveness of computer and other electronic aids for smoking cessation: a systematic review and network meta-analysis.

A Self-Administered Questionnaire to Measure Dependence on Cigarettes: The Cigarette Dependence Scale

Efficacy and Safety of Smoking Cessation Interventions in Patients With Cardiovascular Disease

Contact Info

Product

Resources

About